Enoxaparin-induced hepatotoxicity: clinical cases and literature review
Low molecular weight heparins, in particular enoxaparin, have a wide range of applications, including prevention and treatment of deep vein thrombosis. The most common adverse effects of these drugs are bleeding and thrombocytopenia, but a clinician should be aware of another less common but not le...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
NEW TERRA Publishing House
2021-03-01
|
Series: | Вестник анестезиологии и реаниматологии |
Subjects: | |
Online Access: | https://www.vair-journal.com/jour/article/view/501 |
Summary: | Low molecular weight heparins, in particular enoxaparin, have a wide range of applications, including prevention and treatment of deep vein thrombosis. The most common adverse effects of these drugs are bleeding and thrombocytopenia, but a clinician should be aware of another less common but not less important adverse effect such as an elevated transaminase level. In 2019, we observed two cases of enoxaparin-induced hepatotoxicity. In the first one, enoxaparin 0.4 ml subcutaneously twice a day was prescribed to a 40-year-old woman as a bridge therapy to discontinue warfarin before elective surgery. In the second case, a 27-year-old man received enoxaparin 0.4 ml subcutaneously twice a day for the prevention of deep vein thrombosis. The elevation of transaminase level for more than 3 times above the norm was noted in both patients which required discontinuation of the drug. |
---|---|
ISSN: | 2078-5658 2541-8653 |